How does vismodegib treat basal cell carcinoma (BCC)?
Vismodegib (Erivedge) treats BCC by blocking the Hedgehog signaling pathway, specifically by inhibiting Smoothened (SMO). This pathway helps drive growth of cancer cells in many BCC tumors. By shutting it down, vismodegib can slow or stop tumor growth and shrink lesions in patients with advanced BCC. [1]
What BCC types is vismodegib used for?
Vismodegib is used for advanced basal cell carcinoma, including:
- Locally advanced BCC that is not curable with surgery or radiation
- Metastatic BCC [1]
What do patients typically notice when treatment works?
When vismodegib is effective, tumor shrinkage can occur over time, which may lead to reduction in the size of lesions and related symptoms. The goal in advanced disease is tumor control when standard local treatments are not suitable. [1]
Why does Hedgehog blockade help in BCC?
Many BCC cases rely on abnormal activation of the Hedgehog pathway to sustain tumor growth. Inhibiting SMO disrupts that signaling, limiting the cancer cells’ ability to keep growing and spreading (in metastatic cases). [1]
What limitations matter for advanced BCC?
Because vismodegib is aimed at Hedgehog pathway activity, its use is focused on patients whose disease is advanced and not amenable to curative surgery or radiation. In practice, the decision to use it depends on BCC extent, prior treatments, and whether the cancer is operable or controllable with local therapy. [1]
Sources
1